Non-invasive bladder urothelial carcinoma

Summary

Non-invasive bladder urothelial carcinoma (MONDO:0003930) is a cancer and 7 clinical trials. Top therapeutic interventions include talimogene laherparepvec. A subtype of bladder transitional cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	non-invasive bladder urothelial carcinoma
Mondo ID	MONDO:0003930
DOID	DOID:6571
NCIT	C6188
UMLS	C1336089
MedGen	233466
GARD	0023742
Is cancer (heuristic)	yes

Also known as: non-invasive bladder urothelial carcinoma · stage 0 bladder urothelial cancer · stage 0 bladder urothelial carcinoma · stage 0 bladder urothelial carcinoma aJCC v6 · stage 0 bladder urothelial carcinoma aJCC v6 and v7 · stage 0 bladder urothelial carcinoma aJCC v7 · stage 0 transitional cell carcinoma of bladder · stage 0 transitional cell carcinoma of the bladder · stage 0 transitional cell carcinoma of the urinary bladder · stage 0 transitional cell carcinoma of urinary bladder · stage 0 urinary bladder transitional cell carcinoma

Disease family

This is a subtype of bladder transitional cell carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › urinary bladder disorder › urinary bladder neoplasm › urinary bladder cancer › urinary bladder carcinoma › bladder transitional cell carcinoma › non-invasive bladder urothelial carcinoma

Related subtypes (4): infiltrating bladder urothelial carcinoma, bladder papillary urothelial carcinoma, bladder urachal urothelial carcinoma, bladder sarcomatoid transitional cell carcinoma

Subtypes (1): bladder carcinoma in situ

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE3	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03091660	PHASE3	ACTIVE_NOT_RECRUITING	S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
NCT05037279	PHASE3	RECRUITING	Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)
NCT05768347	PHASE1	ACTIVE_NOT_RECRUITING	Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC
NCT03430687	PHASE1	WITHDRAWN	Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma
NCT05335512	Not specified	NOT_YET_RECRUITING	Intravesical BCG: is the Urinary Bladder Ready to Receive it
NCT04617743	Not specified	UNKNOWN	The Effect of Post-voiding Reisdual Urine on Non-muscle Invasive Bladder Cancer Recurrence and Progression
NCT04647981	Not specified	COMPLETED	Diagnostic Performance Evaluation Study of the Xpert® Bladder Cancer Monitor Test.

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TALIMOGENE LAHERPAREPVEC	4	1